Suppr超能文献

肢端肥大症的雌激素治疗。

Estrogen treatment for acromegaly.

机构信息

Institute of Endocrinology and Metabolism, Rabin Medical Center, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

出版信息

Pituitary. 2012 Dec;15(4):601-7. doi: 10.1007/s11102-012-0426-4.

Abstract

Estrogens have been used in patients with acromegaly since the 1930-1940s, suppressing plasma IGF-1 levels and improving clinical signs and symptoms of acromegaly. Estrogens antagonize GH function at the post-receptor level, inhibiting GH signaling, thus decreasing GH-induced hepatic IGF-1 synthesis. We report our experience with four female patients with active acromegaly, naïve to medical treatment or inadequately controlled by somatostatin receptor ligands (SRLs) or the GH-receptor antagonist. Adding estrogen treatment (contraceptive pills or transdermal estrogen patches) to their ongoing medical treatment, suppressed IGF-1 significantly in all patients, achieving hormonal remission in three of them. We review the available data on the use of estrogens and selective estrogen receptor modulators in acromegaly, and their mechanisms of action. Estrogens could be an alternative, inexpensive adjuvant treatment for females with active acromegaly, who are only partially responding to SRLs or to the GH-receptor antagonist.

摘要

自 20 世纪 30 年代至 40 年代以来,雌激素已被用于治疗肢端肥大症患者,其可降低 IGF-1 水平并改善肢端肥大症的临床体征和症状。雌激素在受体后水平拮抗 GH 功能,抑制 GH 信号转导,从而减少 GH 诱导的肝 IGF-1 合成。我们报告了 4 例女性活动性肢端肥大症患者的经验,这些患者对药物治疗无反应或对生长抑素受体配体(SRL)或生长激素受体拮抗剂的控制不足。在她们现有的治疗方案中添加雌激素治疗(避孕药或经皮雌激素贴片)后,所有患者的 IGF-1 均显著下降,其中 3 例达到了激素缓解。我们回顾了肢端肥大症中使用雌激素和选择性雌激素受体调节剂及其作用机制的现有数据。对于仅对 SRL 或生长激素受体拮抗剂部分反应的女性活动性肢端肥大症患者,雌激素可能是一种替代的、廉价的辅助治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验